HURA
HEALTHCARETuHURA Biosciences Inc
Live · NASDAQ · May 9, Close
What's Moving HURA Today?
No stock-specific AI insight has been generated for HURA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.54
Fundamentals
Trading
HURA News
20 articles- TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028Yahoo Finance·Apr 22, 2026
- Is TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money?Yahoo Finance·Apr 20, 2026
- HURA: 2025 Financial ResultsYahoo Finance·Apr 9, 2026
- TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical OperationsYahoo Finance·Apr 7, 2026
- TuHURA Biosciences, Inc.'s (NASDAQ:HURA) Shift From Loss To ProfitYahoo Finance·Apr 2, 2026
- TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdateYahoo Finance·Apr 1, 2026
- Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related CancersYahoo Finance·Mar 23, 2026
- TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price RequirementYahoo Finance·Feb 27, 2026
- TuHURA Biosciences Announces Participation in Upcoming Investor ConferencesYahoo Finance·Feb 24, 2026
- TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related CancersYahoo Finance·Feb 17, 2026
- TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceYahoo Finance·Feb 12, 2026
- TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous MelanomaYahoo Finance·Feb 2, 2026
- HURA: Focus on the Delta Opioid ReceptorYahoo Finance·Dec 22, 2025
- TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual MilestoneYahoo Finance·Dec 15, 2025
- TuHURA Biosciences Provides Corporate Update Following Recent FinancingYahoo Finance·Dec 11, 2025
- TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct OfferingYahoo Finance·Dec 9, 2025
- TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and ExpositionYahoo Finance·Dec 8, 2025
- HURA: Third Quarter ResultsYahoo Finance·Nov 17, 2025
- TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate UpdateYahoo Finance·Nov 14, 2025
- TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and ExpositionYahoo Finance·Nov 3, 2025
All 20 articles loaded
Price Data
52-Week Range
$2.54
Fundamentals
Trading
About TuHURA Biosciences Inc
TuHURA Biosciences Inc is a leading biotechnology firm focused on pioneering immunotherapy solutions aimed at revolutionizing cancer and autoimmune disease treatment. With a robust pipeline driven by extensive scientific research, the company is dedicated to unlocking the full potential of the human immune system to enhance patient outcomes significantly. TuHURA's strategic partnerships and commitment to innovative technologies position it well for sustainable growth and value creation in the fast-evolving biopharmaceutical sector. As it advances its research and development activities, TuHURA is set to be a transformative player in the future of healthcare.